Skip to main content
. 2015 May 18;10(5):e0127380. doi: 10.1371/journal.pone.0127380

Fig 2. Mutation and drug sensitivity distributions of the CGP dataset.

Fig 2

(A) Sensitivities of BRAF wild type and mutant samples to three BRAF inhibitors, i.e., AZ628, PLX4720 and SB590885. P-values by Wilcoxon Rank Sum test are 3.84e-6, 9.98e-10 and 1.33e-11, respectively. (B) Sensitivities of MEK wild type and mutant samples to four MEK inhibitors. (C) Sensitivities of BRAF wild type and mutant samples to four MEK inhibitors. (D) Drug sensitivity differences between wild type and mutant samples for cancer-related genes in MAPK pathway. Color key indicates log p-value between wild type and gene mutation samples by two-sample Wilcoxon Rank Sum test. (E) Mutation and CPV rates of 13 cancer-related genes in MAPK pathway.